<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00729924</url>
  </required_header>
  <id_info>
    <org_study_id>080536</org_study_id>
    <nct_id>NCT00729924</nct_id>
  </id_info>
  <brief_title>Genetic Predictors of Raltegravir Penetration Into Cerebrospinal Fluid</brief_title>
  <official_title>Genetic Predictors of Raltegravir Penetration Into Cerebrospinal Fluid</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vanderbilt University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being done to find out how much of the drug raltegravir (RGV) gets into&#xD;
      cerebrospinal fluid (CSF), compared to how much get into the blood and to find out if normal&#xD;
      changes in a certain gene in your body affects how much RGV gets into the CSF.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The multidrug efflux transporter P-glycoprotein (P-gp) is expressed in the blood-brain&#xD;
      barrier where it limits entry of substrate drugs into the central nervous system. Raltegravir&#xD;
      (MK-0158), a new HIV-1 integrase inhibitor and potentially major addition to the therapeutic&#xD;
      armamentarium against HIV, is a substrate for P-gp. Studies are warranted to elucidate the&#xD;
      relevance of P-gp transport for raltegravir in the central nervous system.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2008</start_date>
  <completion_date type="Actual">August 2011</completion_date>
  <primary_completion_date type="Actual">February 2011</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Penetration of Raltegravir (RGV) Into Cerebrospinal Fluid (CSF) Based on Plasma Area-under-the-curve.</measure>
    <time_frame>Day 7</time_frame>
    <description>The primary outcome for this study was the ratio of the 4-hour CSF concentration value (ng/mL) to the partial plasma area-under-the-curve 0-4h value (h*ng/mL).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Penetration of Raltegravir (RGV) Into Cerebrospinal Fluid (CSF) Based on Single Plasma Timepoint.</measure>
    <time_frame>Day 7</time_frame>
    <description>This outcome was the ratio of the 4-hour CSF concentration value (ng/mL) to the 4-hour plasma concentration value (ng/mL).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>Open label oral raltegravir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Raltegravir a single 400 mg pill taken orally every 12 hours for a total of 7 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Raltegravir</intervention_name>
    <description>400mg orally every 12 hours for 7 days</description>
    <arm_group_label>Open label oral raltegravir</arm_group_label>
    <other_name>MK-0518</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          1. Able to give informed consent.&#xD;
&#xD;
          2. Negative HIV-1 serology.&#xD;
&#xD;
          3. At least 18 but no more than 55 years of age.&#xD;
&#xD;
          4. Body mass index &lt;30.&#xD;
&#xD;
          5. Estimated creatinine clearance ≥ 50 mL/minute within 30 days prior to study entry.&#xD;
&#xD;
          6. Within 30 days prior to study entry:&#xD;
&#xD;
               -  Absolute neutrophil count ≥ 1,000/mm3.&#xD;
&#xD;
               -  Hemoglobin ≥ 12.5 g/dL for males and ≥ 11.5 g/dL for females.&#xD;
&#xD;
               -  Platelet count ≥ 100,000/mm3.&#xD;
&#xD;
               -  AST, ALT, and total bilirubin within normal range.&#xD;
&#xD;
               -  Alkaline phosphatase &lt; or = 1.5 x upper limit of normal.&#xD;
&#xD;
          7. Female study volunteers of reproductive potential must have a negative serum or urine&#xD;
             pregnancy test performed within 30 days before study entry.&#xD;
&#xD;
          8. Must agree not to participate in a conception process.&#xD;
&#xD;
          9. Drug transporter gene ABCB1 position 3435 genotype C/C or T/T.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          1. Use of any medication that is metabolized by CYP3A or UGT1A1.&#xD;
&#xD;
          2. Anticipated need to take any medication that is metabolized by CYP3A or UGT1A1 during&#xD;
             the study.&#xD;
&#xD;
          3. Active drug use or dependence.&#xD;
&#xD;
          4. Inability to abstain from alcohol-containing beverages, grapefruit, and grapefruit&#xD;
             juice.&#xD;
&#xD;
          5. Serious illness that would interfere with study participation.&#xD;
&#xD;
          6. Hospitalization for any reason or therapy for serious illness within 14 days prior to&#xD;
             study entry.&#xD;
&#xD;
          7. History of hypersensitivity to study drug or its formulation.&#xD;
&#xD;
          8. As determined by the investigator, a significant active or previous history of&#xD;
             cardiovascular, renal, liver, hematologic, neurologic, gastrointestinal, psychiatric,&#xD;
             endocrine, or immunologic disease(s). This is inclusive of chronic illnesses such as&#xD;
             hypertension, coronary artery disease, arthritis, diabetes, any chronic&#xD;
             gastrointestinal conditions that may affect drug absorption, etc.&#xD;
&#xD;
          9. Breast-feeding.&#xD;
&#xD;
         10. Evidence of CNS infection or space occupying lesion by history or physical&#xD;
             examination.&#xD;
&#xD;
         11. History of significant CNS disorder.&#xD;
&#xD;
         12. Prisoners or subjects who are compulsorily detained.&#xD;
&#xD;
         13. ABCB1 position 3435 C/T heterozygosity.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David W Haas, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vanderbilt Therapeutics Clinical Research Site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Johnson DH, Sutherland D, Acosta EP, Erdem H, Richardson D, Haas DW. Genetic and non-genetic determinants of raltegravir penetration into cerebrospinal fluid: a single arm pharmacokinetic study. PLoS One. 2013 Dec 11;8(12):e82672. doi: 10.1371/journal.pone.0082672. eCollection 2013.</citation>
    <PMID>24349334</PMID>
  </results_reference>
  <verification_date>March 2015</verification_date>
  <study_first_submitted>August 4, 2008</study_first_submitted>
  <study_first_submitted_qc>August 7, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 8, 2008</study_first_posted>
  <results_first_submitted>May 27, 2014</results_first_submitted>
  <results_first_submitted_qc>March 2, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 3, 2015</results_first_posted>
  <last_update_submitted>March 2, 2015</last_update_submitted>
  <last_update_submitted_qc>March 2, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 3, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University</investigator_affiliation>
    <investigator_full_name>David Haas</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Raltegravir</keyword>
  <keyword>CSF</keyword>
  <keyword>ABCB1 SNP</keyword>
  <keyword>HIV/AIDS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Raltegravir Potassium</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Raltegravir 400mg Orally Every 12 Hours for 7 Days.</title>
          <description>Raltegravir a single 400mg tablet taken orally every 12 hours for a total of 7 days.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Raltegravir: 400mg Orally Every 12 Hours for 7 Days</title>
          <description>Raltegravir a single 400mg tablet taken orally every 12 hours for a total of 7 days.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="40"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34.5" lower_limit="26.8" upper_limit="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Cerebrospinal Fluid Protein</title>
          <units>mg/dL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33" lower_limit="24" upper_limit="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kilograms</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="74.6" lower_limit="62.6" upper_limit="80.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index</title>
          <units>kilgrams/(meter squared)</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24.0" lower_limit="22.2" upper_limit="25.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>ABCB1 Genotype</title>
          <description>ABCB1 (rs1045642) C/C or T/T Genotype</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>C/C Genotype</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T/T Genotype</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Penetration of Raltegravir (RGV) Into Cerebrospinal Fluid (CSF) Based on Plasma Area-under-the-curve.</title>
        <description>The primary outcome for this study was the ratio of the 4-hour CSF concentration value (ng/mL) to the partial plasma area-under-the-curve 0-4h value (h*ng/mL).</description>
        <time_frame>Day 7</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Raltegravir: 400mg Orally Every 12 Hours for 7 Days (ABCB1 C/C</title>
            <description>Raltegravir a single 400 mg pill taken orally every 12 hours for a total of 7 days in participants with ABCB1 C/C genotype.</description>
          </group>
          <group group_id="O2">
            <title>Raltegravir: 400mg Orally Every 12 Hours for 7 Days (ABCB1 T/T</title>
            <description>Raltegravir a single 400 mg pill taken orally every 12 hours for a total of 7 days in participants with ABCB1 T/T genotype.</description>
          </group>
        </group_list>
        <measure>
          <title>Penetration of Raltegravir (RGV) Into Cerebrospinal Fluid (CSF) Based on Plasma Area-under-the-curve.</title>
          <description>The primary outcome for this study was the ratio of the 4-hour CSF concentration value (ng/mL) to the partial plasma area-under-the-curve 0-4h value (h*ng/mL).</description>
          <units>1/h</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0066" lower_limit="0.0050" upper_limit="0.0081"/>
                    <measurement group_id="O2" value="0.0070" lower_limit="0.0060" upper_limit="0.0095"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The hypothesis was that the ratio of the 4-hour CSF concentration value to the partial plasma area-under-the-curve 0-4h value would differ between participants with ABCB1 C/C and T/T genotypes.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.43</p_value>
            <p_value_desc>The p-value is not adjusted for multiple comparisons.</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Penetration of Raltegravir (RGV) Into Cerebrospinal Fluid (CSF) Based on Single Plasma Timepoint.</title>
        <description>This outcome was the ratio of the 4-hour CSF concentration value (ng/mL) to the 4-hour plasma concentration value (ng/mL).</description>
        <time_frame>Day 7</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Raltegravir: 400mg Orally Every 12 Hours for 7 Days: ABCB1 C/C</title>
            <description>Raltegravir a single 400 mg pill taken orally every 12 hours for a total of 7 days in participants with ABCB1 C/C genotype.</description>
          </group>
          <group group_id="O2">
            <title>Raltegravir: 400mg Orally Every 12 Hours for 7 Days: ABCB1 T/T</title>
            <description>Raltegravir a single 400 mg pill taken orally every 12 hours for a total of 7 days in participants with ABCB1 T/T genotype.</description>
          </group>
        </group_list>
        <measure>
          <title>Penetration of Raltegravir (RGV) Into Cerebrospinal Fluid (CSF) Based on Single Plasma Timepoint.</title>
          <description>This outcome was the ratio of the 4-hour CSF concentration value (ng/mL) to the 4-hour plasma concentration value (ng/mL).</description>
          <units>ratio</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.028" lower_limit="0.014" upper_limit="0.057"/>
                    <measurement group_id="O2" value="0.021" lower_limit="0.016" upper_limit="0.045"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>We explored post-hoc whether the ratio of the 4-hour CSF concentration value to the 2-hour plasma concentration differs between participants with ABCB1 C/C and T/T genotypes.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.43</p_value>
            <p_value_desc>The p-value is not adjusted for multiple comparisons.</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Raltegravir: 400mg Orally Every 12 Hours for 7 Days</title>
          <description>Raltegravir a single 400 mg pill taken orally every 12 hours for a total of 7 days.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>post-lumbar puncture headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>There were no limitations to this trial.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>David W. Haas, MD</name_or_title>
      <organization>Vanderbilt University</organization>
      <phone>615-936-8594</phone>
      <email>david.w.haas@vanderbilt.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

